Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth.The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on McDonald's Corp. MCD — cutting the stock from Buy to Sell — amid growing concern that appetite-suppressing medications such as Novo Nordisk A/S’s NVO Wegovy and Eli Lilly and Co.’s LLY Zepbound are reshaping consumer beh ...

Redburn Atlantic earlier downgraded the shares of blue-chip fast food giant McDonald's Corp (NYSE:MCD) to "sell" form "buy," and cut its price target to $260 from $319. This is the third downgrade MCD has received in three days, with the analyst in coverage citing weight-loss drugs like Ozempic as a critical business threat.MCD earlier slipped to its lowest level since April, as it continues to pull away from a late May attempt to conquer long-term resistance at the $320 region. Shares are today testing sup ...

文章核心观点 - 生物技术公司Viking Therapeutics因开发的减肥药受关注本周股价上涨近18%，世界卫生组织将支持肥胖药物使用，公司药物VK2735若获批有望接近Zepbound和Wegovy的受欢迎程度，且减肥药市场是全球性的 [1][2][5][6] 公司情况 - Viking Therapeutics本周股价在过去五个交易日上涨近18% [1] - Viking Therapeutics的VK2735在2期临床试验中表现出色，若获批上市有望接近Zepbound和Wegovy的受欢迎程度 [5] 行业动态 - 路透社报道世界卫生组织将支持成人使用肥胖药物，并推动改善中低收入患者获取药物的途径 [2] - 美国专门用于减肥的药物以诺和诺德的Wegovy和礼来的Zepbound为首，因比节食和锻炼更容易减肥而受公众欢迎 [4] - 因Wegovy和Zepbound的成功，制药和生物技术公司竞相开发自己的减肥药 [5] - 体重管理不仅是美国的难题，减肥药在全球都有市场 [6]